SecBot SecBot
8-K ·Filed May 7, 2026

VCEL

Vericel Corp
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001628280-26-031713
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong Q1 beat across both franchises (MACI +22%, Burn Care +91%) signal accelerating commercial momentum. The FDA approval for the new manufacturing facility removes a key capacity overhang. Watch for continued MACI implant growth and NexoBrid BARDA contract execution in coming quarters.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAAP net loss of $0.12/share, which is narrower than the $-0.14 Street consensus. The company raised its full-year 2026 revenue guidance by $10M to $326-336M, driven by 22% MACI growth and 91% Burn Care growth, while maintaining profitability margin targets.

Key Financial Metrics

EPS
−$0.12
est −$0.14 · +14.3%
Revenue
$68.4M
est $63.6M · +7.5% · +30.1% YoY
Rating
strong beat
Guidance
$326M-$336M
raised
Free Cash Flow
$15.1M
Gross Margin
72%

Key Facts

  • Total Q1 2026 revenue of $68.4M, up 30% YoY from $52.6M, beating $63.6M consensus
  • GAAP net loss of $6.3M ($0.12/diluted share) vs $11.2M loss ($0.23) in Q1 2025, narrower than $-0.14 Street consensus
  • Full-year 2026 revenue guidance raised by $10M to $326-336M (from $316-326M)
  • MACI revenue grew 22% to $56.4M; Burn Care revenue surged 91% to $12.0M
  • Adjusted EBITDA grew 195% to $9.6M (14% of revenue) from $3.2M (6%)
  • Operating cash flow of $16.4M and free cash flow of $15.1M, vs negative FCF of $7.6M in Q1 2025
  • Received FDA approval for MACI commercial manufacturing at new Burlington facility
  • Announced BARDA award valued at up to $197M for NexoBrid procurement and development

Financial Impact

Revenue beat consensus by ~7.5% ($68.4M vs $63.6M); EPS loss of $0.12 was ~14% better than $-0.14 consensus; full-year guidance raised by $10M (+3.1% at midpoint)

revenueepsguidancecash flowadjusted EBITDA

Risk Factors

  • GAAP net loss persists despite revenue growth; profitability dependent on operating leverage
  • Execution risk on new Burlington facility ramp and MACI manufacturing scale-up
  • Burn Care revenue can be lumpy due to episodic burn events and Epicel ordering patterns

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-031713
Document: vcel-20260507.htm0001628280-26-031713
Document: 0001628280-26-031713-index-headers.html0001628280-26-031713
Document: 0001628280-26-031713-index.html0001628280-26-031713
Document: 0001628280-26-031713.txt0001628280-26-031713
8-K Data (Synthetic)0001628280-26-031713

Track record

30 reports on VCEL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.08% at T+60 after the May 7, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
  4. Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  6. Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  7. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  8. Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
Showing 10 of 30

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026